Cargando…

Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers

BACKGROUND: Systemic bevacizumab is a novel targeted anti-angiogenic therapy for high-output cardiac failure (HOCF) in hereditary hemorrhagic telangiectasia (HHT) but published data is limited. This survey-based study measured physician-reported safety, effectiveness and current treatment practices...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Samkari, Hanny, Albitar, Hasan A., Olitsky, Scott E., Clancy, Marianne S., Iyer, Vivek N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857247/ https://www.ncbi.nlm.nih.gov/pubmed/31727111 http://dx.doi.org/10.1186/s13023-019-1239-6

Ejemplares similares

Screening for pulmonary and brain vascular malformations is the North American standard of care for patients with hereditary hemorrhagic telangiectasia (HHT): A survey of HHT Centers of Excellence
por: Kilian, Alexandra, et al.
Publicado: (2020)

Hereditary Hemorrhagic Telangiectasia (HHT) and Survival: The Importance of Systematic Screening and Treatment in HHT Centers of Excellence
por: de Gussem, Els M., et al.
Publicado: (2020)

Mobile Mitral and Aortic Valvular Masses in Patients With Hereditary Hemorrhagic Telangiectasia Receiving Intravenous Bevacizumab
por: Albitar, Hasan Ahmad, et al.
Publicado: (2020)

Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients
por: Guilhem, Alexandre, et al.
Publicado: (2017)

Executive summary of the 14th HHT international scientific conference
por: Ola, Roxana, et al.
Publicado: (2023)

An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist’s perspective
por: Kritharis, Athena, et al.
Publicado: (2018)

Quality of life in patients with hereditary haemorrhagic telangiectasia (HHT)
por: Zarrabeitia, Roberto, et al.
Publicado: (2017)

Prospective pilot study of Floseal® for the treatment of anterior epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT)
por: Lee, John M., et al.
Publicado: (2019)

A case report of hepatopulmonary syndrome in hereditary hemorrhagic telangiectasia (HHT): Not all right-to-left shunting in HHT is due to pulmonary arteriovenous malformations
por: Krishnan, Sheila, et al.
Publicado: (2018)

Bevacizumab and gastrointestinal bleeding in hereditary hemorrhagic telangiectasia
por: Ou, George, et al.
Publicado: (2016)

Antithrombotic Therapy in Hereditary Hemorrhagic Telangiectasia: Real-World Data from the Gemelli Hospital HHT Registry
por: Gaetani, Eleonora, et al.
Publicado: (2020)

Whole genome sequences discriminate hereditary hemorrhagic telangiectasia phenotypes by non-HHT deleterious DNA variation
por: Joyce, Katie E., et al.
Publicado: (2022)

Ammonia Predicts Hepatic Involvement and Pulmonary Hypertension in Patients With Hereditary Hemorrhagic Telangiectasia
por: Bloom, Patricia P., et al.
Publicado: (2020)

Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia
por: Buscarini, Elisabetta, et al.
Publicado: (2019)

Development and validation of a quality of life measurement scale specific to hereditary hemorrhagic telangiectasia: the QoL-HHT
por: Le, Thi Thao Truc, et al.
Publicado: (2022)

Hereditary Hemorrhagic Telangiectasia Presenting as High Output Cardiac Failure during Pregnancy
por: Goussous, Tareq, et al.
Publicado: (2009)

Two Cases of High Output Heart Failure Caused by Hereditary Hemorrhagic Telangiectasia
por: Cho, Donghyuk, et al.
Publicado: (2012)

A hematologic support score for longitudinal measurement of blood and iron requirements in hereditary hemorrhagic telangiectasia and other chronic bleeding disorders
por: Al‐Samkari, Hanny, et al.
Publicado: (2020)

Hereditary hemorrhagic telangiectasia treated with low dose intravenous bevacizumab
por: Wee, Jee Wan, et al.
Publicado: (2014)

Management of Refractory Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia with Bevacizumab
por: Masood, Muaaz, et al.
Publicado: (2021)

Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia
por: Parambil, Joseph G., et al.
Publicado: (2021)

Hereditary Hemorrhagic Telangiectasia With Liver Vascular Malformation Presenting With High-Output Heart Failure
por: Singh, Gurshawn, et al.
Publicado: (2014)

Topical Propranolol Improves Epistaxis Control in Hereditary Hemorrhagic Telangiectasia (HHT): A Randomized Double-Blind Placebo-Controlled Trial
por: Mei-Zahav, Meir, et al.
Publicado: (2020)

A case report of successful treatment of high-output heart failure secondary to hereditary haemorrhagic telangiectasia with bevacizumab
por: Flower, Mark, et al.
Publicado: (2019)

Endoglin involvement in integrin-mediated cell adhesion as a putative pathogenic mechanism in hereditary hemorrhagic telangiectasia type 1 (HHT1)
por: Rossi, Elisa, et al.
Publicado: (2015)

Healthcare Utilization and Costs associated with Hereditary Hemorrhagic Telangiectasia Patients in a Large US Claims Database
por: Hasan Albitar, Hasan Ahmad, et al.
Publicado: (2020)

Hereditary Hemorrhagic Telangiectasia
por: Kamath, Nagesh, et al.
Publicado: (2015)

European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT)
por: Shovlin, Claire L., et al.
Publicado: (2018)

Severe Hypoxemia Caused by High-Output Heart Failure and Pulmonary Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia
por: Yamamoto, Hiroaki, et al.
Publicado: (2021)

Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia
por: Thompson, Andrew B., et al.
Publicado: (2014)

Bevacizumab to Treat Cholangiopathy in Hereditary Hemorrhagic Telangiectasia: Be Cautious: A Case Report
por: Maestraggi, Quentin, et al.
Publicado: (2015)

Bevacizumab as a treatment for hereditary hemorrhagic telangiectasia in children: a case report
por: Ospina, Fabio E, et al.
Publicado: (2017)

Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia: A case report
por: Huemer, Florian, et al.
Publicado: (2016)

High output cardiac failure in 3 patients with hereditary hemorrhagic telangiectasia and hepatic vascular malformations, evaluation of treatment
por: Olsen, Lilian B., et al.
Publicado: (2020)

Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia
por: Vázquez, Carolina, et al.
Publicado: (2020)

Imaging of Hereditary Hemorrhagic Telangiectasia
por: Carette, Marie-France, et al.
Publicado: (2008)

Impact of Age on Outcomes in Hospitalized Patients with Hereditary Hemorrhagic Telangiectasia
por: Iyer, Vivek N., et al.
Publicado: (2018)

Development and performance of a hereditary hemorrhagic telangiectasia-specific quality-of-life instrument
por: Kasthuri, Raj S., et al.
Publicado: (2022)

High-Output Heart Failure Contributing to Recurrent Epistaxis Kiesselbach Area Syndrome in a Patient With Hereditary Hemorrhagic Telangiectasia
por: Bhattad, Venugopal Brijmohan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fqeqjhusvfro79rhqutg2kplps